by: Parent Project Muscular Dystrophy
Edgewise Therapeutics recently joined PPMD for a community webinar for an update on the company’s sevasemten program in Duchenne and Becker. The Edgewise team reviewed new Open-label Extension MESA data in Becker, as well as interim data from the ongoing LYNX and FOX Phase 2 studies.
